Back to top
more

Dr. Reddys Laboratories (RDY)

(Real Time Quote from BATS)

$78.22 USD

78.22
170,663

-2.22 (-2.76%)

Updated Jul 16, 2024 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (168 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Inflation Pressures

The impact of inflationary headwinds and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and SLGL.

New Strong Buy Stocks for November 17th

PSX, DCP, RDY, PDFS and CRZBY have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2022.

Doctor Reddy's (RDY) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up

Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States.

TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down

TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact.

Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2

Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.

Doctor Reddy's (RDY) is a Top-Ranked Value Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Sol-Gel

Teva, Dr. Reddy's and Sol-Gel have been highlighted in this Industry Outlook article.

Sundeep Ganoria  headshot

3 Generic Drug Stocks to Watch Amid Continued Pricing Pressure

The impact of COVID-19 and pricing pressure on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to TEVA, RDY and SLGL.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Intercept (ICPT) Settles Litigation With Dr. Reddy's for Ocaliva

Intercept (ICPT) enters into a settlement agreement with Dr. Reddy's for lead drug Ocaliva's generic version.

Doctor Reddy's (RDY) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Dr. Reddy's (RDY) Q1 Earnings Increase Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings and sales increase year over year in first-quarter fiscal 2023.

Dr. Reddy's (RDY) Q4 Earnings Decline Y/Y, Sales Increase

Dr. Reddy's (RDY) earnings decline while sales grow year over year in fourth-quarter fiscal 2022.

New Strong Sell Stocks for May 20th

Teaser: CBAN, CHUY, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 20, 2022.

New Strong Sell Stocks for May 18th

ALX, CBAN, and RDY have been added to the Zacks Rank #5 (Strong Sell) List on May 18, 2022.

New Strong Sell Stocks for May 12th

CHUY, RDY, and FBC have been added to the Zacks Rank #5 (Strong Sell) List on May 12, 2022.

Dr. Reddy's (RDY) Q3 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in third-quarter fiscal 2022.

Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

Zacks Industry Outlook Highlights: Dr. Reddy's Laboratories, Teva Pharmaceutical and Amphastar Pharmaceuticals

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid Stabilizing Pricing Pressure

The impact of COVID-19 on the Zacks Medical-Generic Drugs industry remains mixed. The stabilization in price in 2021 and new product launches may provide some respite for RDY, TEVA and AMPH.

New Strong Sell Stocks for November 22nd

RDY, FRO, WWW, PGR, and LGIH have been added to the Zacks Rank #5 (Strong Sell) List on November 22, 2021.

New Strong Sell Stocks for November 4th

ALX, RDY, HSC, LAWS, and ANDE have been added to the Zacks Rank #5 (Strong Sell) List on November 4, 2021.

Amarin (AMRN) Q3 Earnings Top, Vascepa Sales Decline Y/Y

Amarin's (AMRN) reports lower sales volume for its drug, Vascepa, in the United States during the third quarter. The company's stock falls in pre-market trading.

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.